Subscribe
shutterstock_607718810_vchal
vchal / Shutterstock.com
14 November 2019EuropeRory O'Neill

Merck and Evotec strike CRISPR licensing deal

Merck has agreed to license its CRISPR gene-editing technology to German biotech company Evotec.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
USITC investigates grey market IVF products
14 April 2020   The US International Trade Commission is investigating ‘grey market’ in vitro fertilisation products intended for the Turkish market, following a trademark complaint from German pharmaceutical company Merck KGaA.
Big Pharma
EU General Court sides with Merck in TM opposition
21 November 2019   A German individual has lost an appeal before the tribunal of the EU General Court, after his trademark registration was opposed by Merck.
Americas
Sigma-Aldrich submits CRISPR petition at USPTO
23 July 2019   Merck KGaA-owned Sigma-Aldrich has petitioned the US Patent and Trademark Office to open an interference proceeding between its own pending CRISPR-Cas9 patents and patents awarded to the University of California, Berkeley.


Editor's picks

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

Editor's picks

Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

More features

The Quintara decision: Defining trade secrets in federal cases
To disclose or not: Pharma patents face new AI reality
Trade secrets go global: How brand owners face a high-stakes battlefront
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Former pharma GC brings in-house perspective to McGuireWoods
Sandoz eyes US biosimilar launch as Regeneron settles
Buchalter brings in new partner to head up medtech
Trump’s march-in rights threat: Why pharma is rethinking collaborations